Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

Also called NCT06268977

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 482 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06268977
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06268977. Non-randomized; no masking; primary purpose treatment. Start 2025-04-01 (actual); primary completion 2026-01-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct06268977
Content hash
6eb4f09ae82532b69b65717fca7af5c29d3b50c7c7fb990c12bb1162c43ea458